ANT3310

Research use only, not for human use.

ANT3310 is an inhibitor of broad-spectrum covalent Serine β-Lactamase with IC50s ranging from 1 nM to 175 nM for AmpC, CTX-M-15, TEM-1, OXA-48, OXA-23, and KPC-2. ANT3310 can be used in studies about bacterial infection.

ANT3310 is an inhibitor of broad-spectrum covalent Serine β-Lactamase with IC50s ranging from 1 nM to 175 nM for AmpC, CTX-M-15, TEM-1, OXA-48, OXA-23, and KPC-2. ANT3310 can be used in studies about bacterial infection.(In Vitro):ANT3310 shows a low in vitro cytotoxicity (IC50 > 100 μM), cardiotoxicity (inhibition of the hERG potassium ion channel) and genotoxicity in HepG2 cell. ANT3310 (0.006 to 3 000 nM) inhibits a series of Serine β-Lactamase including AmpC, CTX-M-15, TEM-1, OXA-48, OXA-23, and KPC-2, with IC<>50 values ranging from 1 nM to 175 nM.(In Vivo):In male Swiss albino mice, ANT3310 (1 mg/kg; i.v.) shows a T1/2 value of 0.64 h, AUC value of 412 ng?h/mL, and Cl value of 40 mL/min/kg. In the murine thigh infection model, ANT3310 (25, 50 and 100 mg/kg; i.v.) reduces bacterial burdens in a dose-dependent manner to levels below that of the initial starting inoculum at the highest dose, when treated with the combination of MEM.

ANT3310 sodium (Compound 21, 0.006 to 3 000 nM, 10 min) inhibits a series of Serine β-Lactamase (AmpC, CTX-M-15, TEM-1, OXA-48, OXA-23, and KPC-2), with IC<>50 values ranging from 1 nM to 175 nM.ANT3310 sodium shows a low in vitro cytotoxicity (IC<>50: > 100 μM) in HepG2 cell, cardiotoxicity (inhibition of the hERG potassium ion channel), and genotoxicity (Ames test).

ANT3310 sodium (intravenous injection, 25-100 mg/kg, at 1, 3, 5, and 7 h postinfection) reduces bacterial burdens in murine thigh infection model.ANT3310 sodium (intravenous injection, 1 mg/kg, Male Swiss albino mice) shows a T1/2 value of 0.64 h, AUC value of 412 ng?h/mL, and Cl value of 40 mL/min/kg (pharmacokinetic assay). Animal Model:Murine thigh infection modelDosage:25, 50, and 100 mg/kg Administration:Intravenous injection, at 1, 3, 5, and 7 h postinfection Result:Reduced bacterial burdens (colony forming units, CFU) in a dose-dependent manner to levels below that of the initial starting inoculum at the highest dose, when treated with the combination of MEM.

——

GPCR/G Protein

Antibacterial

——

——

——

2410688-61-6

263.2

C6H9FN2NaO5S

>98% (HPLC)

In Vitro:?DMSO : 250 mg/mL (953.51 mM)

O(S(=O)(=O)O)N1[C@H]2C[N@@](C1=O)[C@H](F)CC2.[Na]

——

(-20℃)

With Ice Pack

≥ 2 years